최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Cell, v.173 no.6, 2018년, pp.1439 - 1453.e19
Kim, Miriam Y. (Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine) , Yu, Kyung-Rok (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) , Kenderian, Saad S. (Division of Hematology, Mayo Clinic) , Ruella, Marco (Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine) , Chen, Shirley (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) , Shin, Tae-Hoon (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) , Aljanahi, Aisha A. (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) , Schreeder, Daniel (Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine) , Klichinsky, Michael (Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine) , Shestova, Olga (Center for Cellular) , Kozlowski, Miroslaw S. , Cummins, Katherine D. , Shan, Xinhe , Shestov, Maksim , Bagg, Adam , Morrissette, Jennifer J.D. , Sekhri, Palak , Lazzarotto, Cicera R. , Calvo, Katherine R. , Kuhns, Douglas B. , Donahue, Robert E. , Behbehani, Gregory K. , Tsai, Shengdar Q. , Dunbar, Cynthia E. , Gill, Saar
Summary The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal mye...
Blood Appelbaum 130 2373 2017 10.1182/blood-2017-09-797712 Gemtuzumab ozogamicin for acute myeloid leukemia
Cancer Discov. Behbehani 5 988 2015 10.1158/2159-8290.CD-15-0298 Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Cell Stem Cell Biasco 19 107 2016 10.1016/j.stem.2016.04.016 In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases
Nucleic Acids Res. Brinkman 42 e160 2014 10.1093/nar/gku936 Easy quantitative assessment of genome editing by sequence trace decomposition
Mol. Cell. Biol. Brinkman-Van der Linden 23 4199 2003 10.1128/MCB.23.12.4199-4206.2003 CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice
Immunology Cao 132 18 2011 10.1111/j.1365-2567.2010.03368.x Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?
Science Cong 339 819 2013 10.1126/science.1231143 Multiplex genome engineering using CRISPR/Cas systems
Sci. Transl. Med. Davila 6 224ra25 2014 10.1126/scitranslmed.3008226 Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Nat. Biotechnol. Doench 32 1262 2014 10.1038/nbt.3026 Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation
Donahue Chapter 22 2005 Large animal models for stem and progenitor cell analysis. Curr. Protoc. Immunol
Adv. Hematol. Dutour 2012 683065 2012 10.1155/2012/683065 In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia
Cytometry A Finck 83 483 2013 10.1002/cyto.a.22271 Normalization of mass cytometry data with bead standards
Nat. Biotechnol. Fu 32 279 2014 10.1038/nbt.2808 Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Nature Genovese 510 235 2014 10.1038/nature13420 Targeted genome editing in human repopulating haematopoietic stem cells
Blood Gill 123 2343 2014 10.1182/blood-2013-09-529537 Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Nat. Biotechnol Hsu 31 827 2013 10.1038/nbt.2647 DNA targeting specificity of RNA-guided Cas9 nucleases
J. Biol. Chem. Ishida 289 25341 2014 10.1074/jbc.M113.523480 Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33
Leukemia Kenderian 29 1637 2015 10.1038/leu.2015.52 CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
J. Clin. Oncol. Kochenderfer 33 540 2015 10.1200/JCO.2014.56.2025 Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
Curr. Protoc. Cytom. Kotecha Chapter 10 2010 Web-based analysis and publication of flow cytometry experiments
Blood Rev. Laszlo 28 143 2014 10.1016/j.blre.2014.04.001 The past and future of CD33 as therapeutic target in acute myeloid leukemia
Lancet Lee 385 517 2015 10.1016/S0140-6736(14)61403-3 T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Nature Lek 536 285 2016 10.1038/nature19057 Analysis of protein-coding genetic variation in 60,706 humans
Blood Leong 129 609 2017 10.1182/blood-2016-08-735365 An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Cell Levine 162 184 2015 10.1016/j.cell.2015.05.047 Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis
Blood Mardiros 122 3138 2013 10.1182/blood-2012-12-474056 T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
N. Engl. J. Med. Maude 371 1507 2014 10.1056/NEJMoa1407222 Chimeric antigen receptor T cells for sustained remissions in leukemia
Mol. Ther. Milone 17 1453 2009 10.1038/mt.2009.83 Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
Science Narasimhan 352 474 2016 10.1126/science.aac8624 Health and population effects of rare gene knockouts in adult humans with related parents
Exp. Hematol. Nguyen 34 728 2006 10.1016/j.exphem.2006.03.003 Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs
Science Notta 333 218 2011 10.1126/science.1201219 Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment
J. Anal. At. Spectrom. Ornatsky 23 463 2008 10.1039/b710510j Development of analytical methods for multiplex bio-assay with inductively coupled plasma mass spectrometry
Blood Paul 96 483 2000 10.1182/blood.V96.2.483.014k40_483_490 Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2
Blood Peterson 127 2416 2016 10.1182/blood-2015-09-672337 Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates
Biotechnol Pinello 34 695 2016 Analyzing CRISPR genome-editing experiments with CRISPResso. Nat
Leukemia Pizzitola 28 1596 2014 10.1038/leu.2014.62 Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
Nat. Biotechnol. Qiu 29 886 2011 10.1038/nbt.1991 Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE
Nature Saleheen 544 235 2017 10.1038/nature22034 Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity
Nat. Med. Scott 23 1095 2017 10.1038/nm.4377 Implications of human genetic variation in CRISPR-based therapeutic genome editing
Nat. Methods Shen 11 399 2014 10.1038/nmeth.2857 Efficient gnome modification by CRISPR-Cas9 nickase with minimal off-target effects
Cancer Discov. Sotillo 5 1282 2015 10.1158/2159-8290.CD-15-1020 Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
PLoS One Stemmer 10 e0124633 2015 10.1371/journal.pone.0124633 CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool
Nat. Genet. Sulem 47 448 2015 10.1038/ng.3243 Identification of a large set of rare complete human knockouts
Mol. Ther. Tashiro 25 2202 2017 10.1016/j.ymthe.2017.05.024 Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1
Blood Taussig 106 4086 2005 10.1182/blood-2005-03-1072 Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
J. Biol. Chem. Taylor 274 11505 1999 10.1074/jbc.274.17.11505 The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2
Nat. Methods Tsai 14 607 2017 10.1038/nmeth.4278 CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets
J. Clin. Invest. Turtle 126 2123 2016 10.1172/JCI85309 CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Eur. J. Immunol. Ulyanova 29 3440 1999 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.0.CO;2-C The sialoadhesin CD33 is a myeloid-specific inhibitory receptor
Mol. Ther. Wang 23 184 2015 10.1038/mt.2014.164 Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia
Cell Stem Cell Wu 14 486 2014 10.1016/j.stem.2014.01.020 Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells
J. Exp. Med. Wu 215 217 2018 10.1084/jem.20171341 Geographic clonal tracking in macaques provides insights into HSPC migration and differentiation
Nat. Commun. Yang 5 5507 2014 10.1038/ncomms6507 Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells
Protoc Zunder 10 316 2015 10.1038/nprot.2015.020 Nat
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.